Journal article
Stoichiometry of recombinant cystic fibrosis transmembrane conductance regulator in epithelial cells and its functional reconstitution into cells in vitro
The Journal of biological chemistry, Vol.269(4), pp.2987-2995
1994
DOI: 10.1016/S0021-9258(17)42037-0
PMID: 7507932
Abstract
We have generated several clones of Chinese hamster ovary, mouse epitheloid C127, and pig kidney epithelial LLCPK1 cells producing high levels of functional recombinant human cystic fibrosis transmembrane conductance regulator (CFTR). Processing of CFTR to the mature and fully glycosylated form in these cells is inefficient with only approximately 40% of all newly synthesized CFTR being converted to the mature form. Furthermore, expression of the most frequent mutant allele of the cystic fibrosis (CF) gene, the delta F508 mutant in these epithelial cells, indicated that it is biosynthetically arrested at the endoplasmic reticulum and fails to traffic to the plasma membrane. Using a combination of CFTR mutants and monoclonal antibodies, all the detectable recombinant CFTR in these cells was determined at least under the conditions used, to be present as a monomer. To demonstrate the feasibility of protein replacement therapy, we were able to effect the physical transfer of functional recombinant CFTR produced in Chinese hamster ovary cells to the plasma membranes of Ha3b fibroblasts, a cell line devoid of cAMP-stimulated chloride channels. Transfer of CFTR was mediated by the hemagglutinin viral fusion protein of influenza virus present on the Ha3b cells. Efficiency of transfer was up to 25% of the target cells, and CFTR chloride channel activity was detectable for up to 12 h post-fusion. Therefore, with the development of an appropriate formulation of fusogenic proteoliposome or virosome containing reconstituted purified CFTR, it should be feasible to introduce functional CFTR into CF-affected cells.
Details
- Title: Subtitle
- Stoichiometry of recombinant cystic fibrosis transmembrane conductance regulator in epithelial cells and its functional reconstitution into cells in vitro
- Creators
- John Marshall - Genzyme Corp., Framingham MA 01701, United StatesShaona Fang - Genzyme Corp., Framingham MA 01701, United StatesLynda S Ostedgaard - Genzyme Corp., Framingham MA 01701, United StatesCatherine R O’Riordan - Genzyme Corp., Framingham MA 01701, United StatesDawn Ferrara - Genzyme Corp., Framingham MA 01701, United StatesJane F Amara - Genzyme Corp., Framingham MA 01701, United StatesHenry Hoppe IV - Genzyme Corp., Framingham MA 01701, United StatesRonald K Scheule - Genzyme Corp., Framingham MA 01701, United StatesMichael J Welsh - Genzyme Corp., Framingham MA 01701, United StatesAlan E Smith - Genzyme Corp., Framingham MA 01701, United StatesSeng H Cheng - Genzyme Corp., Framingham MA 01701, United States
- Resource Type
- Journal article
- Publication Details
- The Journal of biological chemistry, Vol.269(4), pp.2987-2995
- DOI
- 10.1016/S0021-9258(17)42037-0
- PMID
- 7507932
- NLM abbreviation
- J Biol Chem
- ISSN
- 0021-9258
- eISSN
- 1083-351X
- Publisher
- American Society for Biochemistry and Molecular Biology; Bethesda, MD
- Language
- English
- Date published
- 1994
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Pulmonary, Critical Care, and Occupational Medicine; Fraternal Order of Eagles Diabetes Research Center; Neurosurgery; Internal Medicine
- Record Identifier
- 9984020717202771
Metrics
10 Record Views